Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 3/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489968 | 0.96 | NR3C2 (0.48) | SMPD1PGRNR3C2ARTLR8 | |
| SCHEMBL3488750 | 0.90 | PGR (0.47) | PGRNR3C2ARALDH1A1SLC34A1 | |
| SCHEMBL13436038 | 0.89 | SMPD1 (0.41) | SMPD1PGRNR3C2ARTLR8 | |
| SCHEMBL3487986 | 0.89 | NR3C2 (0.39) | SMPD1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3488293 | 0.87 | NR3C2 (0.39) | SMPD1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3488225 | 0.86 | NR3C2 (0.49) | SMPD1PGRNR3C2ARRIPK3 | |
| SCHEMBL3488661 | 0.85 | NR3C2 (0.48) | SMPD1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3488809 | 0.84 | ALDH1A1 (0.39) | PGRNR3C2ARALDH1A1SLC34A1 | |
| SCHEMBL3489611 | 0.84 | MAPT (0.52) | PGRNR3C2ALDH1A1SLC34A1MAPT | |
| SCHEMBL3487832 | 0.84 | NR3C2 (0.51) | PGRNR3C2ARALDH1A1SLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | SMPD1 2824/4885PGR 107/4885NR3C2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.